Bank of New York Mellon Corp Purchases 26,316 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Bank of New York Mellon Corp grew its holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 13.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 228,700 shares of the company’s stock after purchasing an additional 26,316 shares during the quarter. Bank of New York Mellon Corp owned about 0.24% of Poseida Therapeutics worth $668,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in PSTX. Vanguard Group Inc. raised its position in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the last quarter. Blair William & Co. IL raised its holdings in Poseida Therapeutics by 41.3% in the 1st quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after acquiring an additional 282,310 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock worth $2,648,000 after acquiring an additional 391,801 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Poseida Therapeutics by 177.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after purchasing an additional 40,245 shares in the last quarter. Finally, Cantor Fitzgerald L. P. bought a new stake in shares of Poseida Therapeutics during the fourth quarter valued at approximately $169,000. 46.87% of the stock is currently owned by institutional investors.

Poseida Therapeutics Stock Down 6.6 %

NASDAQ:PSTX opened at $3.37 on Monday. The stock’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $2.95. The company has a market cap of $327.33 million, a price-to-earnings ratio of -2.83 and a beta of 0.51. Poseida Therapeutics, Inc. has a 52-week low of $1.83 and a 52-week high of $4.27. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48.

Poseida Therapeutics (NASDAQ:PSTX) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The business had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. On average, analysts anticipate that Poseida Therapeutics, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Poseida Therapeutics in a research note on Tuesday, August 6th.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.